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Analysis of survival of end.stage renal disease patients. Traditional life-
table analyses of differences in patient survival for various end-stage
renal disease (ESRD) treatment modalities ignore the fact that ESRD
patients face sequential risks because they frequently experience more
than one mode of therapy. A modification of the usual life-table analysis
is suggested as being more appropriate. This modified method takes
into account the "time-to-treatment" bias, which, in this instance, is
the time spent on the first modality of treatment (that is, center
dialysis). The survival data of more than 2,000 ESRD patients in the
State of Michigan during the 5-year period, 1974 to 1978, are used to
illustrate this method.
Analyse de Ia survie des malades atteints d'affection rénale terminale.
Les tables traditionnelles d'analyse des differences de survie pour
différentes affections rénales au stade terminal ne tiennent pas compte
du fait que ces malades sont confrontés a des risques sequentiels car ils
subissent souvent plus d'une categorie de traitement. Une modification
de ces tables est suggérée. Cette méthode modifiée prend en compte Ic
biais temps-traitement" qui. dans ce cas, est le temps passé dans Ia
premiere modalité therapeutique, c'est-à-dire Ia dialyse en centre. Les
observations des services concernant plus de 2.000 malades de l'Etat de
Michigan (USA) au cours d'une période de 5 ans, 1974 a 1978. sont
utilisées pour illustrer cette mdthode.
Any comparison of group survival data for patients with end-
stage renal disease (ESRD) treated by dialysis with ESRD
patients treated by renal transplantation requires consideration
not only of differences in selection of these population groups
[1] but also of each patient's sequential experience with treat-
ment modalities [2]. Lacking this knowledge, such a compari-
son of data has limitations because of the differences in compo-
sition of the groups. The purpose of this paper is to present a
modified method for analyzing differences in survival between
treatment modalities for ESRD patients.
For comparison, we will present both the standard life-table
method for analyzing survival [3] and the modified method for
statistically analyzing differences in survival between treatment
modalities experienced sequentially by patients. We have used
the standard method for estimating survival percentages for
groups of transplantation and dialysis patients [4]. These stan-
dard comparisons of survival of dialysis and transplant patients
have, however, limited meaning as only the survivors of
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dialysis receive transplants. Survival data of ESRD patients
during a second treatment modality must take into account
survival experience on the first treatment modality [5—71. The
modified life-table method allows removal of patients from the
first treatment group and their accession to the second treat-
ment group. These ideas recently have been used graphically to
describe dialysis and transplantation survival experience in
Europe [8].
This presentation does not analyze the quality of life of ESRD
patients. Although morbidity of ESRD patients is an extremely
important aspect [9], only mortality is studied here. Data on
more than 2,000 ESRD patients treated in Michigan over a 5-
year period are used to compare the modified method with the
standard analysis of patient survival or risk of death for
different consecutive ESRD treatment modalities.
Methods
All 36 ESRD dialysis facilities and the 12 transplantation
centers in the State of Michigan regularly submit data about
each of their patients to the Michigan Kidney Registry (MKR).
In addition, MKR personnel visit each facility twice a year to
verify the accuracy and the completeness of information. Data
are coded and entered into an Amdahl 470 V/7 computer.
Computer programs and manual procedures are used for editing
data files for completeness, consistency, and appropriateness,
as well as for retrieval and analysis of data.
In this study, patients who were receiving home dialysis or
renal transplantation are considered to remain in that treatment
group until death or withdrawal even though they may subse-
quently return to center dialysis. Moreover, the age used for a
patient is the age when treatment was begun for ESRD.
Results
In the 5-year period, January 1974 through December 1978, a
total of 2,493 ESRD patients in the State of Michigan started on
dialysis (hemodialysis or peritoneal dialysis) in a center and/or,
initially or subsequently, went to home dialysis or received a
renal transplant. The longest followup time for any patient was
6 years from start of center hemodialysis. Computation of time
on center dialysis, and of time on a subsequent modality to
which a patient accedes, requires precise starting and ending
dates. Of the 2,493 patients beginning treatment for ESRD
during this interval, 70 patients were excluded from the study
because of imprecise starting dates for initial center dialysis. In
addition, 27 patients had no dialysis prior to first transplanta-
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tion. Arbitrarily, these 27 patients were excluded from all
analyses except that of survival percentage of all ESRD pa-
tients. There were 2,051 patients starting on hemodialysis and
345 starting on peritoneal dialysis, Thus, there were 2,396
patients or 96.1% of the ESRD patients for whom analyses were
made of survival on center dialysis versus survival on other
modalities of treatment. For the analyses by age and race, there
were only 3 patients for whom data on age was missing and 5
patients for whom data on race was missing.
Figure 1 shows the survival rate by the usual life-table
method for the entire group of 2,423 patients, regardless of the
therapy they received (that is, whether they were on dialysis, or
were transplanted, or had both done) and irrespective of the
sequence of therapy. The cumulative survival percentages are
77.8% alive at 1 year and 63.7% at 2 years.
The predominant treatment modality for ESRD was center
hemodialysis. The determination of survival time on center
dialysis was calculated from the time each of the 2,396 patients
began center dialysis until one of the following happened to the
patient: (1) withdrawal alive to a second treatment modality, (2)
withdrawal alive at the end of the followup period, or (3) death.
The survival curve for all 2,396 patients while receiving center
dialysis is shown in Figure 1. The I- and 2-year survival rates
for those patients receiving center dialysis are 78.1% and
61.2%, respectively. The survival curve for the 1,560 patients
who received only center dialysis and did not receive any other
subsequent treatment modality also is presented in Figure 1.
The 1- and 2-year survival rates for those patients who received
only center dialysis is 70.8% and 53.2%, respectively. The
survival rates for all patients receiving center dialysis exceed
the rates for patients receiving only center dialysis, because the
former group includes those patients who survived while on
center dialysis and subsequently underwent another treatment
modality.
From the group of center dialysis patients, 261 individuals
were trained for conducting dialysis at home, with 232 being on
hemodialysis and 29 on peritoneal dialysis. These patients spent
a median time of 4.93 months in the center before going home.
Their survival curve calculated from the day of going home until
withdrawal alive or by death is shown in Figure 2. There were
86.1% alive at 1 year and 75.3% at 2 years. For comparative
purposes, the survival curve of all patients receiving center
dialysis is reproduced on Figure 2.
Selected subsets of ESRD patients are transplanted with
kidneys from related or cadaver donors. Figure 2 shows the
survival curve of the 173 related donor transplant patients with
91.0% alive at 1 year and 89.4% at 2 years. The related donor
transplant patients had a median time on center dialysis of 6.63
months before transplantation. Also shown in Figure 2 is the
survival curve of the 402 patients transplanted with cadaver
kidneys with 75.2% alive at 1 year and 69.1% at 2 years. The
cadaver transplant patients had a median time on center dialysis
of 11.0 months before transplantation. All of these survival
rates in Figure 2 for transplant patients are calculated by the
standard life-table method from the day of the transplant
operation and continuing until withdrawal alive or death,
Because many ESRD patients experience sequential treat-
ment modalities, and because each treatment modality is asso-
ciated with its own mortality rate, valid comparisons of survival
experience for different treatment modalities cannot be made
0
Time, years
Fig. 1. Survival percentage derived by the standard life-table method
plotted against time for all ESRD patients (A; N = 2,423), all center
dialysis patients (LI; N = 2,396), and patients treated only by dialysis in
a center (•; N = 1,560).
from Figure 2. Thus, Figure 2 illustrates a frequently used, but
faulty, analysis that measures survival from variable starting
times, for example, the time of starting home dialysis or receipt
of a transplanted kidney. An analysis of survival rates that
appropriately considers these sequential risks and lends itself
readily to statistical evaluation is needed for comparing differ-
ent ESRD treatment modalities.
The proposed method for statistical analysis presented here is
derived from the Mantel and Byar modification of the life-table
analysis l0J. The Mantel and Byar method has been used in
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Fig. 2. Survival percentage derived by the standard life-table method
plotted against time for related transplant patients (A; N = 173),
cadaver transplant patients (0; N = 402), home dialysis patients (LI; N
= 261), and all center dialysis patients (•; N 2,396).
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Table 1. Comparison of survival on other treatment modalities to that on center dialysis for all ESRD patients and for three age groups
Statistical analysis Sample size
Mantel and Byar method Log-rank test Center dialysis Other treatment
Groups/treatments Odds of death P x2 P At entry At 2 yr At entry At 2 yr
All patients
Home dialysis 0.66 13.02 <0.01 36.72 <0.01 2402 600 261 137
Related transplant 0.26 47.52 <0.01 72.73 <0.01 2402 60! 173 88
Cadaver transplant 0.91 0.96 0.33 23.24 <0.01 2402 601 402 149
15- to 29-yr-old patients
Home dialysis 1.23 0.15 0.70 1.90 0.17 371 61 39 20
Related transplant 0.43 4.13 0.04 21.20 <0.01 371 61 90 47
Cadavertransplant 1.58 2.81 0.09 3.66 0.06 371 61 114 47
30- to 44-yr-old patients
Home dialysis 0.77 0.93 0.34 9.48 <0.01 515 117 71 38
Related transplant 0.40 4.58 0.03 11.87 <0.0l 5l5 117 38 21
Cadavertransplant 1.26 1.46 0.23 3.41 0.06 515 117 151 57
45- to 60-yr-old patients
Home dialysis 0.72 3.54 0.06 14.67 <0.01 845 227 115 62
Related transplant 0.67 0.83 0.36 3.83 0.05 845 227 25 II
Cadaver transplant 1.32 2.76 0.10 1.13 0.29 845 227 112 38
Table 2. Comparison of survival on other treatment modalities to that on center dialysis for ESRD patients by sex and race
Statistical analysis Sample size
Mantel and Byar method Log-rank test Center dialysis Other treatment
Group/treatment Odds of death x2 P P At entry At 2 yr At entry At 2 yr
Sex
Male
Home dialysis 0.60 11.92 <0.01 30.94 <0.0! 1389 331 176 90
Related transplant 0.31 24.40 <0.01 41.23 <0.01 1389 332 101 50
Cadaver transplant 0.92 0.43 0.51 14.92 <0.01 l389 332 258 94
Female
Home dialysis 0.76 2.03 0.15 8.08 <0.01 1013 269 85 47
Related transplant 0.20 22.03 <0.0! 32.42 <0.01 1013 269 72 38
Cadaver transplant 0.86 0.68 0.41 9.36 <0.0! 10l3 269 144 55
Race
White
Home dialysis 0.59 15.81 <0.01 42.31 <0.01 1538 333 218 113
Related transplant 0.25 43.89 <0.01 72.04 <0.01 1538 334 l53 77
Cadaver transplant 0.85 1.63 0.20 22.92 <0.Ol 1538 334 269 95
Black
Home dialysis 1.12 0.14 0.71 0.32 0.57 818 255 40 21
Related transplant 0.49 1.62 0.20 3.05 0.08 818 255 17 8
Cadavertransplant 1.03 0.01 0.91 2.68 0.10 818 255 127 51
analyzing the outcome of patients receiving heart transplants.
Their method deals with the 'time-to-treatment" bias that
exists with the standard life-table method, that is, that 'treat-
ed" patients must have at least survived from the time of
diagnosis to the time of "treatment" and permits comparative
analysis of survival between two sequential treatment modal-
ities. This kind of bias was first described by Gail [II].
In applying the Mantel and Byar analysis to the ESRD
population, a patient starts in the center dialysis treatment
population and then: (1) transfers to one of the other three
treatment modalities, (2) reaches the last followup date, or (3)
dies. The time on a treatment program is calculated to the exact
number of days. Home-dialysis experience is computed starting
with the date on which the patient starts at home, whereas
transplantation experience starts on the date of the operation.
With the Mantel and Byar method, the usual life-table proce-
dure is adapted by allowing accessions to a group. Thus, losses
from the center dialysis group by patients receiving transplants
become accessions to the transplant group. Specifically, this
method is used in this study to compare center dialysis experi-
ence to that of home dialysis, related transplantation, and
cadaver transplantation. Chi-square values, which indicate the
statistical significance of any difference in survival, and odds of
death are used to compare center dialysis experience with each
of the other three modalities of treatment.
Tables I and 2 show survival data analyzed by the Mantel and
Byar method [10]. In Tables I and 2, six additional patients
have been included in the group of patients with center dialysis
experience that were not considered in the analyses presented
in Figures 1 and 2. Five of these six additional patients had no
dialysis before transplantation, experienced early transplant
failure, and were soon placed on dialysis. For these five
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Fig. 3. Survival percentage derived by the Mantel and Byar method
plotted against time for home dialysis patients (LI) and all center
dialysis patients (•; N = 2,40!).
patients, only their time on dialysis was included in the analy-
sis. The survival experience of home dialysis patients compared
with that of center dialysis patients has ax2 value of 13.02 (P <
0.01) with the odds of death being 0.66, that is, 66% of the risk
of death for center dialysis patients (Table I and Fig. 3). Thus,
there is a significantly better survival rate for the home dialysis
group as compared with the center dialysis group after adjust-
ment for the time-to-treatment bias. Also shown in Table 1 and
Figure 4 is a similar analysis for related transplant patients. The
x2 value for related transplant patient survival versus that of
center dialysis patients is 47.52 (P < 0.01) with the odds of
death being 0.26. Therefore, the survival experience for related
transplant patients also is significantly better than that for
center dialysis patients after adjustment for the time-to-treat-
ment bias. This analysis was repeated for cadaver transplants
(Table 1 and Fig. 5). The x2 value comparing the survival
experience of cadaver transplant and center dialysis patients is
0.96(P = 0.33), and the odds of death are 0.91. Thus, there is no
significant difference in the survival experience of these two
groups after adjustment for the time-to-treatment bias. The ap-
parent discrepancy of the odds of death and Figure 5 is due to
the disproportionate number of deaths after 5 years in the
center dialysis groups compared with the cadaver transplant
group.
Similar analyses have been prepared separately for three age
groups (Table 1) and for the ESRD population according to sex
and race (Table 2), For comparative purposes, these tables also
provide results of the usual life-table analysis for corresponding
groups, using the log-rank test originally described by Mantel
[12] and nicely reviewed by Breslow [13] and Peto et al [14].
Sample sizes available for these analyses also are indicated in
Tables 1 and 2.
Discussion
In comparing the survival experience of ESRD patients for
different treatment modalities, it is important to adjust for the
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Fig. 4. Survival percentage derived by the Mantel and Byar method
plotted against time for related transplant patients (Lx) and all center
dialysis patients (•; N 2,402).
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Fig. 5. Survival percentage derived by the Mantel and Bvar method
plotted against time for cadaver transplant patients (0) and all center
dialysis patients (•; N = 2,402).
"time-to-treatment" bias. Mantel and Byar [10] have described
a procedure for just such an analysis. Their method, in this
case, effectively compares treatment modalities for those pa-
tients with the same prior time on center dialysis. Tables 1 and 2
present the results of this analysis applied to data from the
Michigan Kidney Registry. It is of interest to compare these
results to those obtained when the time-to-treatment adjust-
ment is not considered. For this reason, Tables I and 2 also
present the results of the log-rank test, which compares life-
table survival curves derived without this adjustment. In every
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case, the x2 value for the Mantel and Byar method is less than
that obtained by the log-rank test. Thus, differences in survival
experience are less significant when adjustment is made for the
time-to-treatment bias. In fact, for the comparison of cadaver
transplantation to center dialysis, the difference in survival
changes from highly significant to nonsignificant when the time-
to-treatment bias is considered.
For a truly valid analysis of treatment differences in ESRD,
other aspects of patient selection also should be considered.
The selection of population groups for the various ESRD
treatment modalities occurs at a treatment facility. Bias intro-
duced by the selection process may be a major determinant of
the rate of survival for a treatment group in addition to that of
the treatment itself. Furthermore, this paper makes a basic
assumption that is common to most life-table analyses: The
cause of a patient being censored or withdrawn from one group
is independent of the risk of death of the patient. An example of
the difficulty resulting from such an assumption is that if a
patient in danger of dying on dialysis is given an emergency
kidney transplant and dies 1 hour after the operation, all
standard methods credit the survival of the patient until opera-
tion to the dialysis treatment, but credit the death to transplan-
tation. This results in falsely making the first treatment appear
more effective than the second. Conversely, the poor surgical-
risk patient or the older-aged patient may be eliminated from
consideration for a renal transplant, thus remaining in the
dialysis group. By this means, the survival percentage of the
transplant group is increased, whereas that for the dialysis
group is decreased. This importance of the pretreatment clinical
state in determining an ESRD patient's prognosis has been
stressed [1].
In consideration of possible biases, the analyses in Tables I
and 2 have been prepared separately for specific age, race, and
sex groups. Note that when age, race, or sex is controlled,
differences in survival continue to be less significant when
adjustment is made for the time to treatment" bias. In the
comparison of the survival of cadaver transplant patients with
center dialysis patients by the Mantel and Byar test, the
differences are not significant for the specific age groups
considered, or for all ages combined. In contrast, the log-rank
test gives a different result: Cadaver transplant patient survival
rates are not significantly different from those of center dialysis
patients for any of the three age groups, but there is a highly
significant difference for all ages combined. (The effect of small
subgroup sample size must be considered.) For the comparison
of related transplant with center dialysis patients, both the
Mantel and Byar and log-rank tests are significant for all ages
and for the two younger age groups, but the older age group is
not significant by the Mantel and Byar method. In the compari-
son of home and center dialysis patients, the Mantel and Byar
test is not significant for any of the three age groups, even
though for all ages combined it is highly significant. Here again,
subgroup sample size is a factor. In contrast, by the log-rank
test, home dialysis remains significantly different from center
dialysis for the two older age groups, as it is for all ages, but not
for the younger age group. When sex is controlled for, the only
change from the results of the two methods for all ages
combined is that the Mantel and Byar test for the comparison
with home dialysis becomes nonsignificant for females. When
race is controlled for, all tests of significance by both methods
become nonsignificant for the black race.
There is an interesting result in Table 1 relating to the Mantel
and Byar test for comparison of the survival of cadaver
transplant patients to that of center dialysis patients. In this
situation, the odds of death for all ages combined is slightly less
than 1, yet for each of the three age groups considered, the odds
of death are greater than 1. This paradox is not due to a
favorable survival experience of cadaver transplants in the 0 to
14 and 60+ age groups. Indeed, the odds of death for cadaver
transplant patients compared with center dialysis patients was
1.l85forthe0to l4agegroupand ll.407forthebO+ agegroup,
with only four in the 60+ age group. Thus, this paradox is due
to the weight of a relatively large number of individuals in the
60+ age group of center dialysis patients (N = 607) with a
relatively low survival rate. This finding strongly suggests that
valid analyses of differences in outcomes of these two treatment
modalities also must adjust for age.
These results demonstrate that the usual life-table analyses
by the log-rank test provide a more significant difference by
favoring the second treatment modality through ignoring the
risk during prior therapy than do the tests of significance done
by the Mantel and Byar method, which incorporates the experi-
ence of patients on their first treatment modality. Alternative
and more general methods of life-table analyses are available
that also allow for changing therapies through time-dependent
covariates using the Cox proportional hazard model [15]. Spe-
cifically, the paper by Crowley and Hu [16] is a generalization
of the Mantel and Byar paper, which allows for simultaneous
adjustment for patient characteristics and prior therapy without
the problem of small sample sizes that can result from multiple
subgroup analyses. The primary purpose of this paper, howev-
er, is to point out that when the survival experience of ESRD
patients is compared for different treatment modalities such as
dialysis and transplantation, these comparisons should adjust
for the time on prior center dialysis. An analytical method
recently proposed by Mantel and Byar is suggested for such an
adjustment. Based on data from the Michigan Kidney Registry,
adjustment for the time-to-treatment bias tends to reduce the
significance of differences between treatment modalities.
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